ERBB2 and lung carcinoma: Currently, though chemotherapy in combination with immune therapy has become the standard of care for operable lung cancer, evidence for the efficacy of the combination therapy is lacking in HER2-mutated patients and it remains unknown whether the combination therapy has better efficacy than chemotherapy alone.